Amryt Pharma Plc (AMYT) ORD GBP0.06
No change
- Add to watchlist
- Create an alert
- This stock can be held in a
No change
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
No change
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
205.00p
210.00p
241.00p
£366.54 million
205.00p
200.00p
88.50p
n/a
10.00p (5.13%) Previous:
10.00p
21,295
n/a
1,500
Performance
Not available for this stock.
Fundamental data
| Year ending: | 31/12/2019 | 31/12/2018 |
|---|---|---|
| Revenue ($m) | 58.12 | 17.09 |
| Profit before tax ($m) | (66.76) | (30.44) |
| Adjusted EPS (¢): | (86.00) | (402.00) |
| P/E ratio | n/a | n/a |
| PEG | n/a | n/a |
| EPS growth (%) | n/a | n/a |
Values are quoted in the stock's local currency: US dollar
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
To buy shares in , you'll need to have an account. Try our handy filter to explore the different options.
Ready to take your first step?
To invest in , you'll need to open an account.
Try our handy filter to find which one suits you best.
Important Documents
There are no documents available for this stock.
Broker forecasts
Due to changes in how we source investment data, Broker Forecasts are not available. We're sorry for any inconvenience this may cause.
-
NICE approves Amryt's Myalepta for reimbursement in England and Wales
20 January 2021 12:59
-
Amryt gets reimbursement approval for 'Lojuxta' in Saudi Arabia
17 December 2020 13:38
-
Amryt Pharma gets approval for 'Lojuxta' in Brazil
9 December 2020 09:47
-
Amryt Receives Reimbursement Approval from NICE for Myalepta® (metreleptin) in England and Wales
20 January 2021 07:00
-
Amryt Granted Orphan Drug Designation by the FDA for AP103
23 December 2020 07:00
-
Amryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (lomitapide) in Saudi Arabia
17 December 2020 07:00
Recent trade data is unavailable. We will be replacing it, however in the meantime the information is available on the London Stock Exchange website.
Annual & interim reports
Annual & interim reports are not available for this stock.
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.